Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compositions and methods for treating influenza

A kind of influenza and composition technology, applied in the field of compositions and methods for treating influenza, and can solve problems such as long time

Active Publication Date: 2011-07-13
VARIATION BIOTECHNOLOGIES INC
View PDF26 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Additionally, it takes a relatively long time to formulate and prepare sufficient vaccine doses to deal with seasonal increases in influenza infections

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and methods for treating influenza
  • Compositions and methods for treating influenza
  • Compositions and methods for treating influenza

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0172] Example 1: Peptide Synthesis

[0173] All peptides described herein were synthesized by solid phase peptide synthesis (SPPS). Generally, the C-terminal amino acid is linked to a cross-linked polystyrene (or PEG-based) resin through an acid-labile bond formed with a linker molecule. The resin is insoluble in the solvents used in the synthesis, allowing for relatively simple and quick flushing of excess reagents and by-products. The N-terminus is protected with an Fmoc group which is stable in acid but removable by base. Any pendant functional groups are protected with base-stable but acid-labile groups. The synthesis is then based on the incorporation of Fmoc-protected amino acids on N-alpha into growing peptide chains, one end of which remains attached to the solid phase.

[0174] The following is an exemplary SPPS method for making the peptides described herein. To initiate each coupling, the Fmoc group on the NovaPEG resin-bound amino acid / peptide was removed usin...

example 2

[0176] Example 2: Competitive Microneutralization Assay

[0177] In this example, various peptide compositions were evaluated for their ability to bind influenza neutralizing antibodies. Dilute different peptide compositions (see Figure 1 and Tables 1-9 below) with Iscove's Modified Dulbecco's Medium (Iscove's Modified Dulbecco's Medium, IMDM) to be 80 μg / ml, and 50 μl was added to 96 wells in separate wells in a flat bottom microtiter plate (Nunc). Each peptide composition may include all variants, as appropriate (e.g., the 8 INF-HA-3-V3 peptide variants shown in Table 1, the 4 INF-H1-4-V4 peptide variants in Table 4, etc. ). Commercially available anti-influenza sera and human sera were diluted 1 / 40 with IMDM, and 50 μl was added to each well, followed by incubation of the plate at 37° C. for 1 hour. 50 μl containing 1 x 10 5 IMDM of a pfu influenza strain Wisconsin (A / Wis / 67 / 05) or New Caledonia (A / NC / 20 / 99) was added to each well and the plate was incubated at 37°C for...

example 3

[0200] Example 3: ELISPOT analysis

[0201] In this example, the immunogenicity of the peptide composition of Example 1 was tested by measuring activation of human PBMCs (as measured by IFNγ production) in an ELISPOT assay. Multi-screen HTS plates were coated with PBS containing 10 μg / ml anti-mouse IFNγ antibody (mAb AN18, Mabtech, Mariemont, OH) at 4°C (Millipore, Bedford, MA) overnight. Plates were then washed with PBS and blocked with IMDM containing 10% FCS and 100 U / ml penicillin / streptomycin for 1 hour at room temperature. The culture medium was removed, and 2×10 5 Peripheral blood mononuclear cells (PBMC) (200 μl per well) and peptide composition (40 μg / ml, see figure 2and Table 1-9) were mixed, added to each well, and maintained for 2 days. After incubation, the cells were removed, washed with PBS+0.05% Tween 20, and incubated with 1 μg / ml biotin-labeled anti-mouse IFNγ antibody (mAb R4-6A2-biotin, Mabo Technology Co., Ltd.) for 2 hours at room temperature . Aft...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Diameteraaaaaaaaaa
Diameteraaaaaaaaaa
Login to View More

Abstract

The present application provides compositions and methods useful for treating influenza. As described herein, the compositions and methods are based on the development of peptides and peptide combinations which exhibit immunogenic properties against influenza. In some embodiments, the peptide combinations induce a protective response against multiple strains of influenza, e.g., seasonal strains of influenza or even the new pandemic influenza A (H1N1) virus of swine origin.

Description

[0001] Related applications [0002] This application claims priority and rights to PCT Patent Application No. PCT / US08 / 67471, filed June 19, 2008, and US Provisional Application No. 61 / 182614, filed May 29, 2009. The content of said priority application is incorporated herein by reference in its entirety. Background technique [0003] Influenza is a common respiratory infectious disease associated with viruses of the Orthomyxoviridae family. Due to the highly variable nature of the virus, annual vaccination with a vaccine that has been reformulated to take into account variation in strains is usually required. The vaccine composition developed in the United States every year is approved by the Department of Food and Drug Administration Vaccines and the Related Biologicals Advisory Committee of the Food and Drug Administration Vaccines and the Related Biologicals Advisory Committee [0004] Influenza A and B are two types of influenza viruses that cause epidemic human disea...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/03A61K39/39A61P31/16
CPCA61K38/162C12N2760/16122C12N2760/16234C07K14/005C12N2760/16134A61K39/145C12N2760/16222A61K39/00A61K2039/6018A61K2039/542A61K2039/55505A61K2039/55555A61K2039/55561A61K2039/55572A61K39/12A61P31/16A61K39/39A61K2039/55511C07K7/08C07K14/00C12N7/00C12N2760/16171C12N2760/16271
Inventor 弗朗西斯科·迪亚兹-米托马安德烈·奥格雷尔乔斯·V·托里斯戴维·E·安德森
Owner VARIATION BIOTECHNOLOGIES INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com